SITE001-0057

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE001 (USA) (Dr. Reyes) · consented 2022-04-25

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 97); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-23 (study day 102); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 250); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-02-07 (study day 270); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-10 (study day 454); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-03 (study day 600); relationship: Y

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.